Skip to main content

Advertisement

SpringerLink
Log in

Rasburicase in hemolytic uremic syndrome related to Shiga toxin-producing Escherichia coli: a report of nine cases

  • Brief Report
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Background

Hyperuricemia might induce additional renal damage in children with hemolytic uremic syndrome related to Shiga toxin-producing Escherichia coli (STEC-HUS). A few case reports have shown rasburicase to be effective in decreasing serum uric acid (UA) and improving renal function. However, there is only one report on the use of rasburicase in a child with STEC-HUS, which shows satisfactory results. We describe here the safety and efficacy of rasburicase in nine additional cases.

Case-diagnosis/treatment

Data from 9 children (5 females, median age 2 years) who received rasburicase were reviewed. At admission, 6 were dehydrated and 3 euvolemic. Dehydrated patients received saline solution and afterwards, as well as for those initially euvolemic, we aimed to keep a neutral fluid balance. Despite this, urine output did not increase. Baseline creatinine was 3.35 mg/dL (1.47–9.1) and UA 11.4 mg/dL (8.3–19.2). A single dose of rasburicase (0.2 mg/kg) was given 6–8 h after admission, which reduced UA levels to 1.8 mg/dL (0.3–5, p = 0.009) on the next day. However, renal parameters worsen and dialysis had to be initiated. Then, while still on dialysis, a UA rebound occurred in all cases reaching a peak of 8.9 mg/dL (4.5–13.8). Just after a steady increase in urine output, a sustained decline in UA levels concomitantly occurred with an improvement in renal function. At discharge, all patients reached normal UA levels. No side effects were recorded.

Conclusions

Administration of rasburicase in children with STEC-HUS was safe but failed to provide any significant benefit despite fall in serum UA levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ardissino G, Tel F, Possenti I, Testa S, Consonni D, Paglialonga F, Salardi S, Borsa-Ghiringhelli N, Salice P, Tedeschi S, Castorina P, Colombo RM, Arghittu M, Daprai L, Monzani A, Tozzoli R, Brigotti M, Torresani E (2016) Early volume expansion and outcomes of hemolytic uremic syndrome. Pediatrics 137(1)

  2. Balestracci A, Meni Battaglia L, Toledo I, Martin SM, Alvarado C (2018) Blood urea nitrogen to serum creatinine ratio as a prognostic factor in diarrhea-associated hemolytic uremic syndrome: a validation study. Eur J Pediatr 177:63–68

    Article  CAS  Google Scholar 

  3. Khalid M, Andreoli S (2019) Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS). Pediatr Nephrol 34(12):2495–2507

    Article  Google Scholar 

  4. O’Regan S, Rousseau E (1998) Hemolytic uremic syndrome: urate nephropathy superimposed on an acute glomerulopathy? An hypothesis. Clin Nephrol 30:207–210

    Google Scholar 

  5. Hobbs DJ, Steinke JM, Chung JY, Barletta GM, Bunchman TE (2010) Rasburicase improves hyperuricemia in infants with acute kidney injury. Pediatr Nephrol 25:305–309

    Article  Google Scholar 

  6. Hooman N, Otukesh H (2011) Single dose of rasburicase for treatment of hyperuricemia in acute kidney injury: a report of 3 cases. Iran J Kidney Dis 5:130–132

    PubMed  Google Scholar 

  7. Acosta AA, Hogg RJ (2012) Rasburicase for hyperuricemia in hemolytic uremic syndrome. Pediatr Nephrol 27:325–329

    Article  Google Scholar 

  8. Gopakumar KG, Thankamony P, Seetharam S, P K (2017) Treatment of tumor lysis syndrome in children with leukemia/lymphoma in resource-limited settings—efficacy of a fixed low-dose rasburicase. Pediatr Hematol Oncol 34(4):206–211

    Article  CAS  Google Scholar 

  9. Ejaz AA, Mu W, Kang DH, Roncal C, Sautin YY, Henderson G, Tabah-Fisch I, Keller B, Beaver TM, Nakagawa T, Johnson RJ (2007) Could uric acid have a role in acute renal failure? Clin J Am Soc Nephrol 2(1):16–21

    Article  CAS  Google Scholar 

  10. Ejaz AA, Johnson RJ, Shimada M, Mohandas R, Alquadan KF, Beaver TM, Lapsia V, Dass B (2019) The role of uric acid in acute kidney injury. Nephron 142(4):275–283

    Article  CAS  Google Scholar 

  11. Ake JA, Jeacic S, Ciol MA, Watkins SL, Murray KF, Christie DL, Klein EJ, Tarr PI (2005) Relative nephroprotection during Escherichia coli O157: H7 infections: association with intravenous volume expansion. Pediatrics 115:e673–e680

    Article  Google Scholar 

  12. Wilson FP, Berns JS (2012) Onco-nephrology: tumor lysis syndrome. Clin J Am Soc Nephrol 7(10):1730–1739

    Article  CAS  Google Scholar 

  13. Sinha R, Dugar P (2013) Rasburicase for acute kidney injury. Indian Pediatr 50(11):1051–1052

    Article  Google Scholar 

  14. Balestracci A, Martin SM, Toledo I (2012) Hyperuricemia in children with post-diarrheal hemolytic uremic syndrome. Pediatr Nephrol 27(8):1421–1422

    Article  Google Scholar 

  15. Dinnel J, Moore BL, Skiver BM, Bose P (2015) Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy. Core Evid 10:23–38

    PubMed  PubMed Central  CAS  Google Scholar 

  16. Patel C, Wilson CP, Ahmed N, Hattab Y (2019) acute uric acid nephropathy following epileptic seizures: case report and review. Case Rep Nephrol 2019:4890287

    PubMed  PubMed Central  Google Scholar 

  17. Yu X, Liu L, Nie X, Li J, Zhang J, Zhao L, Wang X (2017) The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis. J Clin Pharm Ther 42(1):18–26

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nephrology Unit, Hospital General de Niños Pedro de Elizalde, Montes de Oca 40, CP 1270, Buenos Aires, Argentina

    Alejandro Balestracci, Luciana Meni Battaglia, Sandra Mariel Martin & Ismael Toledo

Authors
  1. Alejandro Balestracci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luciana Meni Battaglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sandra Mariel Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ismael Toledo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alejandro Balestracci.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics

The study was performed in accordance with the ethical standards of the institutional research and ethics committee.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Balestracci, A., Meni Battaglia, L., Martin, S.M. et al. Rasburicase in hemolytic uremic syndrome related to Shiga toxin-producing Escherichia coli: a report of nine cases. Pediatr Nephrol 35, 1133–1137 (2020). https://doi.org/10.1007/s00467-020-04528-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-020-04528-0

Keywords

Search

Navigation